Pharming Group N.V. (PHAR) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
PHAR Profit Margin, ROE & Profitability Analysis
PHAR vs Healthcare Sector: How Pharming Group N.V. Compares
How Pharming Group N.V. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Pharming Group N.V. Stock Overvalued? PHAR Valuation Analysis 2026
Based on fundamental analysis, Pharming Group N.V. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Pharming Group N.V. Balance Sheet: PHAR Debt, Cash & Liquidity
PHAR Revenue Growth, EPS Growth & YoY Performance
PHAR SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Pharming Group N.V. (CIK: 0001828316)
📋 Recent SEC Filings
❓ Frequently Asked Questions about PHAR
What is the AI rating for PHAR?
Pharming Group N.V. (PHAR) has an AI grade of N/A with 0% confidence, based on fundamental analysis of SEC EDGAR filings.
What are PHAR's key strengths?
Claude: Analysis in progress.
What are the risks of investing in PHAR?
Claude: Analysis in progress.
What is PHAR's revenue and growth?
Pharming Group N.V. reported revenue of N/A.
Does PHAR pay dividends?
Pharming Group N.V. does not currently pay dividends.
Where can I find PHAR SEC filings?
Official SEC filings for Pharming Group N.V. (CIK: 0001828316) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is PHAR's EPS?
Pharming Group N.V. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is PHAR's fundamental grade?
Based on our AI fundamental analysis in May 2026, Pharming Group N.V. has a N/A grade with 0% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is PHAR stock overvalued or undervalued?
Valuation metrics for PHAR: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is PHAR's AI grade for 2026?
Our dual AI analysis gives Pharming Group N.V. a combined N/A grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is PHAR's free cash flow?
Pharming Group N.V.'s operating cash flow is N/A, with capital expenditures of N/A.
How does PHAR compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio N/A (avg: 2).